Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook

Share:
Related MRK
vTv Therapeutics Shares Initiated With Buy Rating, $13 Target
The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen
Deutsche Bank's Losses Affecting the Market on Thursday (GuruFocus)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Merck & Co. (NYSE: MRK), and raised the price target from $46.00 to $48.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Merck & Co. closed on Tuesday at $45.51.

Latest Ratings for MRK

DateFirmActionFromTo
Sep 2016JefferiesMaintainsHold
Sep 2016BarclaysMaintainsOverweight
Aug 2016UBSMaintainsBuy

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!